文献速递心脏核医学

新型CZT SPECT/CT相机定量心肌99mTc-HMDP摄取在转甲状腺素蛋白相关心脏淀粉样变性中的可行性研究

Quantitation of myocardial 99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use?
PubMed 文献 · J Nucl Cardiol · 2020-07-26

本研究探讨使用全身CZT SPECT/CT相机(DNM670CZT)通过SUV定量评估疑似心脏ATTR患者心肌99mTc-HMDP摄取的可行性。15例疑似心脏ATTR(Perugini≥2)患者和15例阴性对照(Perugini<2)分别接受常规平面显像和胸部SPECT/CT。结果显示ATTR患者心脏HMDP SUVmax、%ID、胸肌摄取和心/肺SUVmax比值均显著高于对照组,骨摄取无差异。

要点

  • 全身CZT SPECT/CT相机可定量心肌99mTc-HMDP SUVmax,ATTR患者显著高于对照。
  • ATTR组心脏%ID、胸肌摄取及心/肺SUVmax比值均显著高于对照组。
  • 两组间骨摄取无统计学差异。

核心结论

  • 使用全身SPECT/CT CZT相机定量测量疑似心脏ATTR患者心肌99mTc-HMDP SUVmax具有可行性。

研究设计与样本

  • 研究纳入15例疑似心脏ATTR(Perugini≥2)患者和15例显像阴性(Perugini<2)对照。
  • 患者接受常规99mTc-HMDP平面显像和DNM670CZT胸部SPECT/CT。
  • 在包含左心室的心脏感兴趣区(VOI)计算SUVmax(mg·L-1)和注射剂量百分比(%ID),并在肺、右侧胸大肌和胸骨放置VOI,计算心/肺SUVmax比值(HLR)。

主要发现

  • ATTR患者心脏HMDP SUVmax为12.2±3.7 mg·L-1,对照组为3.5±1.2,P<.0001。
  • ATTR组%ID为1.1±0.3,对照组为0.15±0.8,P<.0001。
  • ATTR组胸肌摄取为1.5±0.3,对照组为0.9±0.3,P<.0001。
  • ATTR组HLR为9.7±3,对照组为4.3±2.2,P<.0001。
  • 两组骨摄取无统计学差异。

临床怎么用

  • 对于疑似心脏ATTR患者,可采用全身CZT SPECT/CT相机进行99mTc-HMDP SUVmax定量评估,辅助诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to investigate the feasibility of assessing absolute myocardial 99mTc-HMDP uptake in patients with suspected cardiac ATTR using SUV with a whole-body CZT SPECT-CT camera (DNM670CZT). METHODS: Fifteen patients with suspected cardiac ATTR (Perugini ≥ 2) underwent a conventional 99mTc-HMDP planar imaging and a thoracic SPECT/CT using a DNM 670CZT. A control group consisted of 15 patients with negative scintigraphy (Perugini < 2). SUVmax (mg·L-1) and percentage of injected dose (%ID) were calculated in a cardiac volume of interest (VOI) encompassing the left ventricle. VOIs were also placed in the lung, the right pectoris major, and the sternum. A heart-to-lung SUVmax ratio (HLR) was calculated. RESULTS: All ATTR patients demonstrated an increased cardiac HMDP SUVmax (12.2 ± 3.7 mg·L-1) vs controls (3.5 ± 1.2, P < .0001). Percentage of ID, pectoral uptake and HLR were significantly higher in the ATTR group (1.1 ± 0.3 vs 0.15 ± 0.8, P < .0001; 1.5 ± 0.3 vs 0.9 ± 0.3, P < .0001; 9.7 ± 3 vs 4.3 ± 2.2, P < .0001). Bone uptake was not statistically different between the two groups. CONCLUSION: This study demonstrated the feasibility of quantitative 99mTc-HMDP SUVmax measurement using a whole-body SPECT/CT CZT camera in patients with suspected cardiac ATTR.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Bellevre D, Bailliez A, Delelis F, et al. Quantitation of myocardial 99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use? J Nucl Cardiol. 2020. PMID: 32715418. doi:10.1007/s12350-020-02274-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。